NASDAQ:FRLN • US35655L2060
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for FREELINE THERAPEUTICS HOLDIN (FRLN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-11-28 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-10-18 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-08-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-16 | Stifel | Maintains | Hold -> Hold |
| 2023-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-01 | Stifel | Reiterate | Hold -> Hold |
| 2023-05-31 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-05 | Stifel | Downgrade | Buy -> Hold |
| 2023-04-05 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-22 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-11 | BTIG | Maintains | Buy |
| 2022-02-01 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-01-07 | Redburn Partners | Upgrade | Neutral -> Buy |
| 2021-11-29 | BTIG | Initiate | Buy |
| 2021-08-18 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-17 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-05-19 | HC Wainwright & Co. | Initiate | Buy |
| 2021-05-06 | Guggenheim | Initiate | Buy |
| 2021-04-06 | Morgan Stanley | Maintains | Overweight |
| 2021-03-23 | Mizuho | Initiate | Buy |
| 2021-03-02 | Stifel | Initiate | Buy |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A -100.00% | N/A | N/A 190.69% | N/A 55.12% | N/A 13.00% | N/A 150.93% | N/A 16.53% | ||||||
| EBITDA YoY % growth | -40.01M | -62.1M -55.21% | -100.54M -61.90% | -137.61M -36.87% | -95.12M 30.88% | N/A 8.84% | N/A 77.34% | N/A 183.35% | N/A 23.93% | N/A 33.67% | N/A 22.56% | N/A | N/A | |
| EBIT YoY % growth | -40.98M | -63.64M -55.30% | -102.45M -60.98% | -140M -36.65% | -96.86M 30.81% | N/A 24.56% | N/A 71.13% | N/A 169.79% | N/A 24.04% | N/A 37.43% | N/A 24.39% | N/A 283.54% | N/A 36.05% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -17.36 65.82% | -25.95 -49.48% | N/A 97.48% | N/A -1,214.84% | N/A 135.65% | N/A -150.67% | N/A 3.95% | N/A 88.36% | N/A 167.65% | N/A 452.17% |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.18 97.89% | -0.17 96.02% | -0.13 96.81% | -0.15 34.78% | -0.16 11.11% |
| Revenue Q2Q % growth | -100.00% | -100.00% | |||
| EBITDA Q2Q % growth | -16.218M 2.01% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -14.535M 20.53% | -12.24M 35.37% | -13.158M 25.83% | -14.688M -20.36% | -16.626M -14.39% |
All data in USD
8 analysts have analysed FRLN and the average price target is 8.41 USD. This implies a price increase of 29.86% is expected in the next year compared to the current price of 6.48.
FREELINE THERAPEUTICS HOLDIN (FRLN) will report earnings on 2024-02-29, after the market close.
The consensus EPS estimate for the next earnings of FREELINE THERAPEUTICS HOLDIN (FRLN) is -0.18 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering FREELINE THERAPEUTICS HOLDIN (FRLN) is 8.